Chiauranib
Small moleculeexperimental
Clinical trial activity
16 trials · 11 clinical orgs · 0 marketing orgs
Phase 1
9
Phase 2
10
Phase 3
2
Phase 4
0
Earliest trial started Feb 1, 2014 (NCT02122809)
Timeline
Indications
Studied for
- Carcinoma, Hepatocellular · Phase 1
- Drugs, Investigational · Phase 3
- Healthy Volunteers · Phase 1
- Lymphoma, Non-Hodgkin · Phase 1/Phase 2
- Neoplasms · Phase 1/Phase 2
- Ovarian Neoplasms · Phase 3
- Paclitaxel · Phase 3
- Pancreatic Neoplasms · Phase 2
- Sarcoma · Phase 2
- Small Cell Lung Carcinoma · Phase 3
- Triple Negative Breast Neoplasms · Phase 2
Mechanism of action
AURKB inhibitor
Vascular endothelial growth factor receptor inhibitor
Chemistry & pharmacology
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL3545428 ↗
Also known as
- chiauranib
- chiauranib
- cs-2164
- cs-2164
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06492915 | Phase 2 | Aug 1, 2024 | Chipscreen Biosciences, Ltd., Fudan University |
| NCT05271292 | Phase 1/Phase 2 (Phase 2) | Aug 26, 2022 | Chipscreen Biosciences, Ltd., Gabrail Cancer Center |
| NCT05505825 | Phase 1/Phase 2 (Phase 2) | Aug 26, 2022 | Akeso Pharmaceuticals, Inc., Chipscreen Biosciences, Ltd., Jilin University |
| NCT05497843 | Phase 2 | Aug 2, 2022 | Chipscreen Biosciences, Ltd., Sun Yat-Sen University |
| NCT05371899 | N/A | Jul 20, 2022 | Chipscreen Biosciences, Ltd., Soochow University |
| NCT05346601 | Phase 1 | Jun 2, 2022 | Chipscreen Biosciences, Ltd., H & J CRO International, Inc., Suzhou Medical College |
| NCT05336721 | Phase 2 | Nov 5, 2021 | Chipscreen Biosciences, Ltd. |
| NCT04921527 | Phase 3 | Jul 1, 2021 | Chipscreen Biosciences, Ltd., Fudan University |
| NCT04830813 | Phase 3 | Mar 5, 2021 | Chipscreen Biosciences, Ltd., Peking University |
| NCT03974243 | Phase 1/Phase 2 (Phase 2) | Jul 31, 2019 | Chipscreen Biosciences, Ltd. |
| NCT03901118 | Phase 2 | Jun 30, 2019 | Chipscreen Biosciences, Ltd., Fudan University |
| NCT03245190 | Phase 1 | Apr 28, 2018 | Chipscreen Biosciences, Ltd. |
| NCT03216343 | Phase 1 | Nov 9, 2017 | Chipscreen Biosciences, Ltd. |
| NCT03166891 | Phase 1/Phase 2 (Phase 2) | Jun 1, 2017 | Chipscreen Biosciences, Ltd. |
| NCT03074825 | Phase 1 | May 9, 2017 | Chipscreen Biosciences, Ltd. |
| NCT02122809 | Phase 1 | Feb 1, 2014 | Chinese Academy of Medical Sciences, Chipscreen Biosciences, Ltd. |
Showing 16 of 16 trials
Page 1 / 1
Organizations
Research & Development (11)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Chipscreen Biosciences, Ltd. | For profit | 16 | 15 | 4 | 2014 |
| Fudan University | Academic/Hospital | 3 | 0 | 2 | 2019 |
| Akeso Pharmaceuticals, Inc. | For profit | 1 | 1 | 1 | 2022 |
| Chinese Academy of Medical Sciences | Academic/Hospital | 1 | 0 | 1 | 2014 |
| Gabrail Cancer Center | Academic/Hospital | 1 | 0 | 1 | 2022 |
| H & J CRO International, Inc. | For profit | 1 | 0 | 1 | 2022 |
| Jilin University | Academic/Hospital | 1 | 0 | 1 | 2022 |
| Peking University | Academic/Hospital | 1 | 0 | 1 | 2021 |
| Soochow University | Academic/Hospital | 1 | 0 | 1 | 2022 |
| Sun Yat-Sen University | Academic/Hospital | 1 | 0 | 1 | 2022 |
| Suzhou Medical College | Academic/Hospital | 1 | 0 | 1 | 2022 |
11 organizations
Page 1 / 1